Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricNVONovo Nordisk A/SNVSNovartis AGAZNAstraZeneca PLC
Snapshot
Price$49.29$154.07$168.69
Market cap$210.12B$261.56B$284.73B
Valuation
P/E12.2x20.7x25.3x
Forward P/E10.5x19x18.9x
Growth
Revenue growth8.1%5.8%9.9%
EPS growth16.7%9.3%33.7%
Profitability
Net margin37.2%24.1%17.2%
ROE66.4%31.7%22.3%
Balance sheet & cash
Debt / equity0.67x0.77x0.61x
Free cash flow yield37.3%4.2%3.1%
Dividend yield3.6%2.9%1.7%
Verdict
Investment ratingStrong· 79Favorable· 67Favorable· 62

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearNVOtoday $49NVStoday $154AZNtoday $169
2027$43.15 – $63.29+28% CAGR$126.26 – $185.19+20% CAGR$169.17 – $248.11+47% CAGR
2028$50.37 – $73.88+22% CAGR$137.97 – $202.35+15% CAGR$226.19 – $331.75+40% CAGR
2029$58.80 – $86.24+20% CAGR$150.76 – $221.11+13% CAGR$302.44 – $443.58+38% CAGR
2030$68.64 – $100.67+20% CAGR$164.73 – $241.61+12% CAGR$404.40 – $593.11+37% CAGR
2031$80.12 – $117.51+19% CAGR$180.00 – $264.01+11% CAGR$540.72 – $793.05+36% CAGR
5-yr CAGR10.2% – 19.0%3.2% – 11.4%26.2% – 36.3%